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Abstract
Previously, we reported that 4-amino-2H-benzo[h]chromen-2-one (ABO) and 4-amino-7,8,9,10-
tetrahydro-2H-benzo[h]chromen-2-one (ATBO) analogues, which were developed from the lead
natural produce neo-tanshinlactone, are potent cytotoxic agents. In order to improve on their water
solubility, the diamino analogues and related salts were designed. All synthesized compounds
were assayed for cytotoxicity, and selected compounds were evaluated for in vivo anti-mammary
epithelial proliferation activity in wild-type mice and mice predisposed for mammary tumors due
to Brca1/p53 mutations. The new derivatives 10, 16 (ABO), 22, and 27 (ATBO) were the most
active analogues with IC50 values of 0.038–0.085 μM in the cytotoxicity assay. Analogue 10
showed around 50-fold improved water solubility compared with the prior lead ABO compound 4-
[(4'-methoxyphenyl)amino]-2H-benzo[h]chromen-2-one (3). Compounds 3, 4, 10, and 22
significantly reduced overall numbers of mammary cells as indicated by the reduction of
mammary gland branching in mutant mice. A one-week treatment with 10 resulted in 80%
reduction in BrdU-positive cells in the cancer prone mammary gland. These four compounds had
differential effects on cellular proliferation and apoptosis in wild-type mouse and mouse model of
human breast cancers. Compound 10 merits further development as a promising anticancer clinical
trial candidate.
Water solubility of a drug and its behavior in water are critical to the bioavailability of
pharmacological preparations.1 Drugs administered orally as a solid must first dissolve in
the aqueous gastric fluid, and then can be absorbed and transported through the systemic
circulation to their site of action.2 Even when drugs enter the circulatory system, their water
solubility can not only influence subsequent bioavailability, but also may lead to side effects
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such as crystallization in the kidney, possibly resulting in kidney damage.3 Therefore, water-
soluble derivatives could have superior pharmacokinetic properties compared with poorly
soluble ones. Due to the importance of this issue, new analogues with a reasonable degree of
water solubility must be designed at an early stage of drug development. Since water
solubility depends on a compound’s chemical structure, the structures and incorporated
functional groups may be modified to improve the water solubility.4,5 A useful approach is
to install polar functional groups, such as acidic or basic groups, which can also be
converted to salts that have better water solubility.6,7
4-Amino-2H-benzo[h]chromen-2-one (ABO, 1) and 4-amino-7,8,9,10-tetrahydro-2H-
benzo[h]chromen-2-one (ATBO, 2) analogues were previously reported as potent cytotoxic
agents. These compounds were developed based on neo-tanshinlactone, a natural product
isolated from the Chinese drug “Tanshen” (Salvia miltiorrhiza Bunge; Lamiaceae) (Figure
1).8,9 The specific compounds 3 and 4 were extremely potent against a panel of human
tumor cell lines with nanomolar IC50 values. Moreover, the synthetic pathway to the
analogues was quite efficient, which greatly increases their chemical availability. However,
these prior inhibitory compounds have limited water solubility, which could adversely affect
their in vivo efficacy and make formulation difficult. Previous studies also suggested that
compounds with an amino functional group, which can impart higher polarity and be
converted to a salt form, exhibited improved water solubility without any loss in the
inhibitory potency.7 Motivated by these results, a series of diamino analogues was designed
to improve water solubility and explore the structure-activity relationships (SAR). The anti-
mammary epithelial proliferation and apoptosis-promoting activities of the lead compounds
was examined with in vivo wild-type and Brca1/p53 mouse mammary models of human
breast cancer. Individuals who inherit a mutation of either the BRCA1 or p53 gene have
increased risk of breast cancer. Brca1/p53 mutant mice are predisposed to mammary tumor.
The mammary gland of Brca1/p53 mutant mice undergoes extensive proliferation and ductal
branching.10 Herein, the design and synthesis of new diamino analogues, the effect of amino
groups on water solubility, and antitumor activity of lead compounds both in vitro and in
vivo are reported.
Based upon previous experience, the R group in Scheme 1 can accommodate various
substituents without dramatic drops in antitumor potency. Therefore, analogues 7–12 and
19–23 were designed to increase overall polarity and allow further conversion to the related
salts. Aniline, piperidine, and aminonaphythylene groups were incorporated to study the
effect of amino position and group size. All target compounds, 7–12 and 19–23, as well as
their salts, 13–18 and 24–28, were synthesized from chlorides 5 and 6 according to methods
reported before (Scheme 1).8 Treatment of 5 and 6 with various amines afforded the related
diamino analogues 7–12 and 19–23, respectively, which were converted to their salt forms,
13–18 and 24–28, respectively, with 3 N HCl in methanol.
All synthesized analogues, 7–28, were tested for in vitro cytotoxic activity against a panel of
human tumor cell lines according to previously published methods (Table 1).11 Cell lines
included KB (nasopharyngeal carcinoma), KB-vin (vincristine-resistant MDR KB subline),
A549 (non-small-cell lung cancer), DU145 (prostate cancer cell line), and SK-BR-3
(estrogen receptor negative, HER2 over-expressing breast cancer).
Among the ABO analogues, the 4'-aniline analogue 10 was the most potent compound with
IC50 values of 0.038–0.055 μM. It was about ten-fold more active than 7, suggesting that the
presence of an unsubstituted primary amine is preferable to a dimethyl-substituted tertiary
amine. Analogue 10 was also about two-fold more active than 9 and significantly more
active than 8. Thus, the rank order of activity based on position of the NH2 group was 4'-
(10) > 3'- (9) ≫ 2'- (8) anilino. The piperidine analogue 11 showed only moderate activity,
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while the aminonaphthalene analogue 12 was equally potent to the 3'-anilino analogue 9.
These results indicated that the aromatic ring connected directly at the 4-amino position led
to better activity. The salt forms 13–18 also displayed potent cytotoxic activity, comparable
to that of their free bases 7–12. The ATBO analogues, 19–23, and the salt forms, 24–28,
exhibited similar SAR to the ABO analogues. With IC50 values of 0.053–0.074 μM, 22 and
its salt form 27 were the most potent ATBO analogues and showed similar or slightly lower
activity compared with the corresponding ABO analogues 10 and 16. This finding suggested
that the aromaticity of ring A was not strongly correlated with the activity.
In order to investigate the water solubility of the new analogues, lead compound 10 was
selected and its water solubility was measured using an HPLC assay,12 with 3 and 1-
naphthol as controls. As shown in Table 2, 10 (33.9 mg/L) was about 50-fold more water
soluble than 3 (0.69 mg/L). The measured water solubility of 1-naphthol was 1050 mg/L
compared with 1350 mg/L reported in the literature.13
Subsequently, lead compounds 3, 4, 10, and 22 were selected for evaluation of in vivo
antiproliferative activity. In addition to studying the effects of these compounds on wild-
type mammary glands, the effects on Brca1/p53-mutated glands, which have extensive
proliferation and ductal branching and are cancer-prone,10,11 were investigated for
comparison. The vehicle-treated Brca1/p53-mutated glands had significantly more
branching, a phenotype similar to the untreated Brca1/p53 mutant mouse.10 All four tested
compounds resulted in considerable reduction of branching in the mutant mouse.
Specifically, lead compounds 3, 4, 10, and 22 reduced mammary gland branching in the
Brca1/p53-mutated glands by 75%, 65%, 69%, and 70%, respectively, after ten days of daily
injection of 0.1 mg of the compound (Figure 2). These compounds also reduced branching
in the wild-type mice, but to lesser degrees ranging from 15–46%.
Interestingly, BrdU-positive populations, which are indicative of cells undergoing DNA
synthesis, were significantly reduced by 55% and 81% in mutant mice treated with
compounds 3 and 10, respectively, relative to vehicle-treated mice. The effects were not
pronounced in the mammary gland of wild-type mice (Figure 3). However, the BrdU-
positive populations in mutant mice increased approximately 90% upon treatment with 4,
but did not change appreciably upon treatment with 22. These latter results indicate that
compound 4 could enhance cell proliferation and might not be best for the prevention or
treatment of mammary tumor.
The total cell numbers are a net result of cell proliferation and apoptosis. Activated cleaved
caspase-3 is required for the execution of apoptosis.14,15 Immunohistochemical staining
with antibodies recognizing cleaved caspase-3 was performed using the paraffin-embedded
mammary gland.16 Compounds 10 and 22 induced 4.8- and 4.5-fold increases, respectively,
in the numbers of apoptotic cells in the Brca1/p53-mutant gland compared to vehicle-treated
glands (Figure 4). In the wild-type mice, 2.1- and 4.0-fold increases in apoptosis were seen
after treatment with compounds 10 and 22, respectively. No conclusive data were obtained
from 3- and 4-treated mice due to the high background staining (data not shown). While the
dosage responses and the effects on tumors remain to be studied, the in vivo data show that
both compounds 10 and 22 reduced branching and increased apoptosis (Figures 2 and 4);
however, only compound 10 reduced cell proliferation (Figure 3). Compound 22
significantly increased apoptosis in the mammary glands of both wild-type and mutant mice.
Taken together, further studies using compound 10 are warranted.
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1H NMR spectra were measured on a 300 or 400 MHz Varian Gemini 2000 spectrometer
using TMS as internal standard. The solvent used was CDCl3 unless indicated. Mass spectra
were measured on a Shimadzu LC-MS2010 instrument. Thin-layer chromatography (TLC)
and preparative TLC were performed on precoated silica gel GF plates purchased from
Merck, Inc. Isco Companion systems were used for flash chromatography. Silica gel (200–
400 mesh) from Aldrich, Inc., was used for column chromatography. All other chemicals
were obtained from Aldrich, Inc, and Fisher, Inc. All compounds were >95% pure on the
basis of HPLC conditions.
Spectroscopic and Analytical Data for New Compounds
4-{[4'-(Dimethylamino)phenyl]amino}-2H-benzo[h]chromen-2-one (7)—1H NMR
(400 MHz, DMSO-d6): δ 9.27 (s, 1H, NH), 8.38 (d, 1H, J = 6.8 Hz, Ar-H), 8.25 (d, 1H, J =
8.8 Hz, Ar-H), 8.04–8.06 (m, 1H, Ar-H), 7.88 (d, 1H, J = 9.2 Hz, Ar-H), 7.71–7.74 (m, 2H,
Ar-H), 7.20 (d, 2H, J = 9.2 Hz, Ar-H), 6.83 (d, 2H, J = 9.2 Hz, Ar-H), 5.14 (s, 1H, 3-H),
2.95 (s, 6H, N(CH3)2). HRMS m/z [M++1] calcd for C21H18N2O2 , 331.1446, found
331.1451. HPLC (80% ACN): 99.8%, RT 1.944 min.
4-[(2'-Aminophenyl)amino]-2H-benzo[h]chromen-2-one (8)—1H NMR (400 MHz,
CD3OD): δ 8.52 (d, 1H, J = 6.8 Hz, Ar-H), 8.12 (d, 1H, J = 8.8 Hz, Ar-H), 8.00 (d, 1H, J =
8.0 Hz, Ar-H), 7.86 (d, 1H, J = 8.8 Hz, Ar-H), 7.69–7.71 (m, 2H, Ar-H), 7.13–7.20 (m, 2H,
Ar-H), 6.92 (d, 1H, J = 8.0 Hz, Ar-H), 6.78 (t, 1H, J = 7.6 Hz, Ar-H), 5.08 (s, 1H, 3-H).
HRMS m/z [M+-1] calcd for C19H14N2O2, 301.0977, found 301.0985. HPLC (70% ACN):
99.9%, RT 1.817 min.
4-[(3′, -Aminophenyl)amino]-2H-benzo[h]chromen-2-one (9)—1H NMR (400
MHz, DMSO-d6): δ 9.24 (s, 1H, NH), 8.39 (d, 1H, J = 6.4 Hz, Ar-H), 8.25 (d, 1H, J = 8.8
Hz, Ar-H), 8.05 (d, 1H, J = 6.4 Hz, Ar-H), 7.89 (d, 1H, J = 8.8 Hz, Ar-H), 7.73 (s, 2H, Ar-
H), 7.13 (t, 1H, J = 8.0 Hz, Ar-H), 6.60 (s, 1H, Ar-H), 6.51 (s, 2H, Ar-H), 5.43 (s, 1H, 3-H),
5.33 (s, 2H, NH2). HRMS m/z [M+-1] calcd for C19H14N2O2, 301.0977, found 301.0983.
HPLC (70% ACN): 99.6%, RT 1.776 min.
4-[(4'-Aminophenyl)amino]-2H-benzo[h]chromen-2-one (10)—1H NMR (400
MHz, DMSO-d6): δ 9.19 (s, 1H, NH), 8.37 (d, 1H, J = 7.6 Hz, Ar-H), 8.24 (d, 1H, J = 9.2
Hz, Ar-H), 8.04 (d, 1H, J = 6.8 Hz, Ar-H), 7.87 (d, 1H, J = 8.4 Hz, Ar-H), 7.71–7.75 (m,
2H, Ar-H), 7.03 (d, 1H, J = 8.0 Hz, Ar-H), 6.67 (d, 1H, J = 8.0 Hz, Ar-H), 5.27 (s, 1H, NH),
5.09 (s, 1H, 3-H). HRMS m/z [M+-1] calcd for C19H14N2O2, 301.0977, found 301.0985.
HPLC (70% ACN): 98.7%, RT 1.727 min.
4-[(1'-Benzylpiperidin-4'-yl)amino]-2H-benzo[h]chromen-2-one (11)—1H NMR
(400 MHz, CDCl3): δ 8.57–8.60 (m, 1H, Ar-H), 7.83–7.85 (m, 1H, Ar-H), 7.61–7.68 (m,
3H, Ar-H), 7.41 (d, 1H, J = 8.4 Hz, Ar-H), 7.26–7.34 (m, 5H, Ar-H), 5.43 (s, 1H, 3-H), 5.18
(d, 1H, J = 7.2 Hz, NH), 3.55 (s, 2H, 4'-NCH2), 3.49–3.52 (m, 1H, 1'-H), 2.91 (d, 2H, J = 12
Hz, 3' and 5'-H), 2.13–2.21 (m, 4H, 2', 3', 5' and 6'-H), 1.66–1.72 (m, 2H, J = 12 Hz, 2'and
6'-H). HRMS m/z [M++1] calcd for C25H24N2O2, 385.1916, found 385.1919. HPLC (80%
ACN): 98.2%, RT 2.167 min.
4-[(5'-Aminonaphthalen-1-yl)amino]-2H-benzo[h]chromen-2-one (12)—1H NMR
(400 MHz, CD3OD): δ 8.53 (d, 1H, J = 8.8 Hz, Ar-H), 8.25 (d, 1H, J = 8.8 Hz, Ar-H), 8.12
(d, 1H, J = 7.2 Hz, Ar-H), 8.03 (d, 1H, J = 7.2 Hz, Ar-H), 7.91 (d, 1H, J = 8.4 Hz, Ar-H),
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7.64–7.76 (m, 2H, Ar-H), 7.53–7.54 (m, 2H, Ar-H), 7.28 (s, 2H, Ar-H), 6.87–6.89 (m, 1H,
Ar-H). HRMS m/z [M+-1] calcd for C23H16N2O2, 351.1133, found 351.1148. HPLC (70%
ACN): 99.8%, RT 1.940 min.
4-{[4'-(Dimethylamino)phenyl]amino}-2H-benzo[h]chromen-2-one
hydrochloride (13)—1H NMR (400 MHz, DMSO-d6): δ 9.32 (s, 1H, NH, D2O
exchanged ), 8.38 (d, 1H, J = 8.0 Hz, Ar-H), 8.26 (d, 1H, J = 9.2 Hz, Ar-H), 7.91–8.06 (m,
1H, Ar-H), 7.87 (d, 1H, J = 8.8 Hz, Ar-H), 7.69–7.76 (m, 2H, Ar-H), 7.27 (d, 2H, J = 8.0
Hz, Ar-H), 7.00 (s, 2H, Ar-H), 5.20 (s, 1H, 3-H, D2O exchanged), 2.99 [s, 6H, N(CH3)2].
4-[(2'-Aminophenyl)amino]-2H-benzo[h]chromen-2-one hydrochloride (14)—1H
NMR (400 MHz, DMSO-d6): δ 9.15 (s, 1H, NH, D2O exchanged), 8.37–8.39 (m, 1H, Ar-
H), 8.29 (d, 1H, J = 9.2 Hz, Ar-H), 8.05–8.07 (m, 1H, Ar-H), 7.89 (d, 1H, J = 8.8 Hz, Ar-H),
7.70–7.76 (m, 2H, Ar-H), 7.15–7.20 (m, 2H, Ar-H), 6.96 (d, 1H, J = 7.6 Hz, Ar-H), 6.80 (t,
1H, J = 7.2 Hz, Ar-H), 4.80 (s, 1H, 3-H, D2O exchanged).
4-[(3'-Aminophenyl)amino]-2H-benzo[h]chromen-2-one hydrochloride (15)—1H
NMR (400 MHz, DMSO-d6): δ 9.36 (s, 1H, NH), 8.38–8.40 (m, 1H, Ar-H), 8.27 (d, 1H, J =
8.8 Hz, Ar-H), 8.05–8.08 (m, 1H, Ar-H), 7.90 (d, 1H, J = 9.2 Hz, Ar-H), 7.70–7.77 (m, 2H,
Ar-H), 7.26 (t, 1H, J = 8.0 Hz, Ar-H), 7.70–7.27 (m, 2H, Ar-H), 6.74–6.85 (m, 3H, Ar and
NH2), 6.51 (s, 1H, Ar-H), 5.49 (s, 1H, 3-H).
4-[(4'-Aminophenyl)amino]-2H-benzo[h]chromen-2-one hydrochloride (16)—1H
NMR (400 MHz, DMSO-d6): δ 9.43 (s, 1H, NH, D2O exchanged ), 8.38 (d, 1H, J = 8.0 Hz,
Ar-H), 8.26 (d, 1H, J = 8.8 Hz, Ar-H), 8.06–8.08 (m, 1H, Ar-H), 7.82 (d, 1H, J = 8.8 Hz,
Ar-H), 7.71–7.76 (m, 2H, Ar-H), 7.38 (d, 1H, J = 8.4 Hz, Ar-H), 7.21 (d, 1H, J = 8.0 Hz,
Ar-H), 6.88 (s, 1H, NH, D2O exchanged), 5.33 (s, 1H, 3-H, D2O exchanged).
4-[(1'-Benzylpiperidin-4'-yl)amino]-2H-benzo[h]chromen-2-one hydrochloride
(17)—1H NMR (400 MHz, DMSO-d6): δ 10.22 (s, 1H, NH), 8.35–8.37 (m, 1H, Ar-H), 8.20
(d, 1H, J = 9.2 Hz, Ar-H), 8.01–8.04 (m, 1H, Ar-H), 7.83 (d, 1H, J = 9.2 Hz, Ar-H), 7.67–
7.74 (m, 2H, Ar-H), 7.49–7.61 (m, 5H, Ar-H), 5.49 (s, 1H, 3-H), 4.31 (d, 2H, J = 4.8 Hz, 4'-
NCH2), 3.79–3.81 (m, 1H, 1'-H), 3.46 (d, 2H, J = 11.6 Hz, 3' and 5'-H), 3.10 (dd, 2H, J =
10.4, 23.2 Hz, 3' and 5'-H), 2.18 (d, 2H, J = 12.8 Hz, 2'and 6'-H), 1.97 (dd, 2H, J = 12.4,
24.8 Hz, 2’and 6’-H).
4-[(5'-Aminonaphthalen-1'-yl)amino]-2H-benzo[h]chromen-2-one
hydrochloride (18)—1H NMR (400 MHz, DMSO-d6): δ 9.72 (s, 1H, NH, D2O
exchanged), 8.38–8.43 (m, 2H, Ar-H), 8.16–8.18 (m, 1H, Ar-H), 8.10 (d, 1H, J = 8.0 Hz,
Ar-H), 7.96 (d, 1H, J = 8.8 Hz, Ar-H), 7.12–7.77 (m, 2H, Ar-H), 7.56–7.58 (m, 2H, Ar-H),
7.27–7.32 (m, 2H, Ar-H), 6.96 (s, 1H, Ar-H), 4.62 (s, 1H, 3-H, D2O exchanged).
4-{[4'-(Dimethylamino)phenyl]amino}-7,8,9,10-tetrahydro-2H-
benzo[h]chromen-2-one (19)—1H NMR (400 MHz, DMSO-d6): δ 9.02 (s, 1H, NH),
7.94 (d, 1H, J = 8.4 Hz, Ar-H), 7.14 (d, 2H, J = 8.8 Hz, Ar-H), 7.09 (d, 1H, J = 8.4 Hz, Ar-
H), 6.80 (d, 2H, J = 9.2 Hz, Ar-H), 5.01 (s, 1H, 3-H), 2.94 (s, 6H, N(CH3)2), 2.82 (t, 2H, J =
5.6 Hz, 10-H), 2.76 (t, 2H, J = 6.0 Hz, 7-H), 1.75–1.81 (m, 4H, 8 and 9-H). HRMS m/z
[M++1] calcd for C21H22N2O2, 335.1760, found 335.1762. HPLC (70% ACN): 97.6%, RT
2.656 min.
4-[(2'-Aminophenyl)amino]-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one
(20)—1H NMR (400 MHz, DMSO-d6): δ 8.81 (s, 1H, NH), 7.95 (d, 1H, J = 8.4 Hz, Ar-H),
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7.06–7.10 (m, 2H, Ar-H), 7.00 (dd, 1H, J = 8.0, 1.2 Hz, Ar-H), 6.82 (dd, 1H, J = 8.0, 1.2 Hz,
Ar-H), 6.61–6.65 (m, 1H, Ar-H), 5.02 (s, 2H, NH2), 4.62 (s, 1H, 3-H), 2.82 (t, 2H, J = 6.0
Hz, 10-H), 2.76 (t, 2H, J = 6.0 Hz, 7-H), 1.74–1.81 (m, 4H, 8 and 9-H). HRMS m/z [M+-1]
calcd for C19H18N2O2, 305.1290, found 305.1297. HPLC (85% ACN): 99.9%, RT 1.690
min.
4-[(3'-Aminophenyl)amino]-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one
(21)—1H NMR (400 MHz, DMSO-d6): δ 8.99 (s, 1H, NH), 7.95 (d, 1H, J = 8.4 Hz, Ar-H),
7.06–7.10 (m, 2H, Ar-H), 6.53–6.55 (m, 1H, Ar-H), 6.44–6.48 (m, 2H, Ar-H), 5.31 (s, 1H,
3-H), 5.28 (s, 2H, NH2), 2.82 (t, 2H, J = 6.0 Hz, 10-H), 2.76 (t, 2H, J = 6.0 Hz, 7-H), 1.74–
1.81 (m, 4H, 8 and 9-H). HRMS m/z [M+-1] calcd for C19H18N2O2, 305.1290, found
305.1298. HPLC (70% ACN): 99.2%, RT 1.946 min.
4-[(4'-Aminophenyl)amino]-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one
(22)—1H NMR (400 MHz, CD3OD): δ 7.78 (d, 1H, J = 8.0 Hz, Ar-H), 7.10 (d, 1H, J = 8.4
Hz, Ar-H), 7.04–7.06 (m, 2H, Ar-H), 6.79–6.82 (m, 2H, Ar-H), 5.23 (s, 1H, 3-H), 2.88 (t,
4H, J = 6.0 Hz, 7 and10-H), 1.85–1.87 (m, 4H, 8 and 9-H). HRMS m/z [M+-1] calcd for
C19H18N2O2, 305.1290, found 305.1298. HPLC (70% ACN): 99.9%, RT 1.904 min.
4-[(1'-Benzylpiperidin-4-yl)amino]-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-
one (23)—1H NMR (400 MHz, CD3OD): δ 7.71 (d, 1H, J = 8.4 Hz, Ar-H), 7.27–7.35 (m,
5H, Ar-H), 7.04 (d, 1H, J = 8.4 Hz, Ar-H), 5.27 (s, 1H, 3-H), 3.57 (s, 2H, 4'-NCH2), 3.52–
3.55 (m, 1H, 1'-H), 2.98 (d, 2H, J = 12 Hz, 3' and 5'-H), 2.85 (dd, 4H, J = 11.2, 5.2 Hz, 7
and 10-H, 2'and 6'-H), 2.19–2.25 (m, 2H, 2’and 6’-H), 2.03 (d, 2H, J = 12.8 Hz, 3' and 5'-H),
1.72–1.87 (m, 6H, 8, 9, 2'and 6'-H). HRMS m/z [M+-1] calcd for C25H28N2O2, 387.2072,
found 387.2097. HPLC (60% ACN): 99.2%, RT 4.439 min.
4-{[4'-(Dimethylamino)phenyl]amino}-7,8,9,10-tetrahydro-2H-
benzo[h]chromen-2-one hydrochloride (24)—1H NMR (400 MHz, DMSO-d6): δ
9.09 (s, 1H, NH, D2O exchanged), 7.94 (d, 1H, J = 8.4 Hz, Ar-H), 7.22 (d, 2H, J = 6.8 Hz,
Ar-H), 7.09 (d, 3H, J = 8.4 Hz, Ar-H), 7.01 (s, 2H, NH2, D2O exchanged), 5.08 (s, 1H, 3-H,
D2O exchanged), 2.99 [s, 6H, N(CH3)2], 2.82 (t, 2H, J = 5.6 Hz, 10-H), 2.76 (t, 2H, J = 6.0
Hz, 7-H), 1.75–1.81 (m, 4H, 8 and 9-H).
4-[(2'-Aminophenyl)amino]-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one
hydrochloride (25)—1H NMR (400 MHz, DMSO-d6): δ 8.92 (s, 1H, NH, D2O
exchanged), 7.99 (d, 1H, J = 8.4 Hz, Ar-H), 7.09–7.19 (m, 3H, Ar-H), 6.98 (t, 1H, J = 8.0
Hz, Ar-H), 6.82 (t, 1H, J = 8.0 Hz, Ar-H), 4.68 (s, 1H, 3-H, D2O exchanged), 2.83 (t, 2H, J
= 6.0 Hz, 10-H), 2.77 (t, 2H, J = 6.0 Hz, 7-H), 1.75–1.81 (m, 4H, 8 and 9-H).
4-[(3'-Aminophenyl)amino]-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one
hydrochloride (26)—1H NMR (400 MHz, DMSO-d6): δ 9.23 (s, 1H, NH, D2O
exchanged), 7.97 (d, 1H, J = 8.4 Hz, Ar-H), 7.38 (t, 1H, J = 8.0 Hz, Ar-H), 7.12 (d, 1H, J =
8.4 Hz, Ar-H), 7.05 (s, 2H, Ar-H), 5.42 (s, 1H, 3-H, D2O exchanged), 2.83 (t, 2H, J = 6.0
Hz, 10-H), 2.77 (t, 2H, J = 6.0 Hz, 7-H), 1.74–1.81 (m, 4H, 8 and 9-H).
4-[(4'-Aminophenyl)amino]-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one
hydrochloride (27)—1H NMR (400 MHz, DMSO-d6): δ 9.23 (s, 1H, NH, D2O
exchanged), 7.96 (d, 1H, J = 8.4 Hz, Ar-H), 7.37 (d, 2H, J = 8.4 Hz, Ar-H), 7.27 (d, 2H, J =
8.4 Hz, Ar-H), 7.12 (d, 1H, J = 8.4 Hz, Ar-H), 6.93 (s, 1H, NH2), 5.25 (s, 1H, 3-H, D2O
exchanged), 2.83 (t, 2H, J = 6.0 Hz, 10-H), 2.77 (t, 2H, J = 6.0 Hz, 7-H), 1.74–1.81 (m, 4H,
8 and 9-H).
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one hydrochloride (28)—1H NMR (400 MHz, DMSO-d6): δ 10.35 (s, 1H, NH), 7.88 (d,
1H, J = 8.4 Hz, Ar-H), 7.58–7.61 (m, 2H, Ar-H), 7.48–7.50 (m, 3H, Ar-H), 7.31 (d, 1H, J =
7.6 Hz, NH), 7.02 (d, 1H, J = 8.4 Hz, Ar-H), 5.31 (s, 1H, 3-H), 4.28 (d, 2H, J = 5.2 Hz, 4'-
NCH2), 3.70–3.72 (m, 1H, 1’-H), 3.26–3.77 (m, 2H, 3' and 5'-H), 3.07 (dd, 2H, J = 10.4,
23.2 Hz, 3' and 5'-H), 2.79 (t, 2H, J = 6.0 Hz, 10-H), 2.73 (t, 2H, J = 6.0 Hz, 7-H), 2.12 (d,
2H, J = 14.0 Hz, 2’& 6’-H), 1.93 (dd, 2H, J = 11.2, 23.6 Hz, 2’and 6’-H), 1.73–1.78 (m, 4H,
8 and 9-H).
Brca1fp/fp p53fp/fp Cre Mutant Mice
Generation of Brca1fp/fpp53fp/fpCre and p53fp/fpCre mice has been described previously.10,17
The mice were in a C57BL/6 and 129/Sv, mixed background. All animal experiments were
performed in accordance with guidelines of federal and Institutional Animal Care and Use
Committee at the University of California, Irvine.
Treatment with 3, 4, 10, 22
Three-month-old mice were treated with 0.1 mg of 3 or 4, 10, 22 or vehicle daily for 10
days. The concentration of stock solution of 3 or 4, 10, 22 was 1 mg/mL in
dimethylsulfoxide. A mixture of 10 μL of stock solution, 30 μL of 40% polyethylene glycol,
and 60 μl of 0.9% NaCl solution was prepared at the time of treatment. Vehicle includes all
solution except 3, 4, 10, or 22. Vehicle or compound was administered i.p. every day for 11
days.
Histology and Immunohistochemistry
The fourth pair glands were dissected and spread on a glass slide. After fixation with
Carnoy’s fixative for three h, the tissues were hydrated and stained in Carmine alum
overnight as described
(http://mammary.nih.gov/tools/histological/Histology/index.html#a1). Branching points in
three random areas totaling approximately 2 mm2 were counted. For histological section,
tissues were fixed in 4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO) at 4 °C
overnight followed by paraffin embedding. Paraffin sections were stained with hematoxylin
and eosin and examined by light microscopy. Immunostaining was performed following the
protocol described in the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA.).
To retrieve the antigen, slides were heated for 20 min in 10 mM citrate buffer, pH 6.0, in a
microwave oven. BrdU monoclonal antibody (GeneTex Inc. Irvine, CA) at 1:1000 dilution,
and cyclin D1 polyclonal rat antibody (NeoMarkers/Thermo Fisher Scientific, Fremont, CA)
at 1:500 dilution, respectively, were used for immunostaining.
Rabbit polyclonal antibodies against cleaved caspase-3 [Gene Tex (cat#GTX86952)] were
used. Mammary tissue sections were paraffin embedded, and cut into 5-μm sections.
Antigen retrieval was performed with citrate buffer (pH 6.0) followed by boiling.
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Structures of natural product neo-tanshinlactone, ABO (1)/ATBO (2) scaffolds, and lead
compounds 3 and 4
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Mammary gland whole mounts (left) of vehicle and 3, 4, 10, and 22 treated 3-month-old
mice and number of branching points (right) in wild-type (wt) and
Brca1f11/f11p53f5&6/f5&6Crec mammary glands are shown after treatment with 0.1 mg of
compound daily for 10 days. Compounds 3, 4, 10, and 22 decreased mammary ductal
branching, especially in Brca1f11/f11p53f5&6/f5&6Crec mice.
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The effects of compounds 3, 4, 10, and 22 on mammary epithelial proliferation are shown.
BrdU-containing drinking water was provided during the last three days of treatment. Cells
that took up BrdU, indicative of DNA synthesis, were detected by immunostaining (left).
BrdU-positive cells in 15 mammary ducts were quantified as the average numbers of BrdU-
positive cells in vehicle and 3, 4, 10, and 22 treated wild-type (wt) and
Brca1f11/f11p53f5&6/f5&6Crec mice (right).
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Immunohistochemical staining of paraffin-embedded mammary gland sections treated with
compounds 10 and 22 (left) shows cytoplasmic and perinuclear localization of cleaved
caspase-3. The compounds had a significant effect on mammary apoptosis as indicated by
the increased percentages of activated caspase-3-positive cells/duct (right).
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Reagents and conditions: (a) amine, EtOH, reflux (ethylene glycol for 11 and 12, 160 °C);
(b) 3 N HCl, MeOH.
Dong et al. Page 13

























































































































































































































































































































































































































































































































































































































































































































































































































Dong et al. Page 16
Table 2
Water solubility of 3, 10, and 1-naphthol
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